Harvard big-shots Kevin Eggan and Clifford Woolf launch ALS startup with exclusive Q-State tech
A group of well-known Harvard professors has launched a new ALS spinout to take on research Big Pharma wasn’t tackling fast enough.
The new company, called QurAlis (pronounced “cure-al-is”), was founded by a couple of stem cell pioneers at Harvard: Kevin Eggan (the guy who developed the first ALS patient-derived stem cell models) and Clifford Woolf. The duo teamed up with two other co-founders, including QurAlis’ CEO Kasper Roet and Jonathan Fleming, who heads up Eggan’s other startup Q-State Biosciences.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
